Back to top
more

Retrophin, Inc. (RTRX)

(Delayed Data from NSDQ)

$19.72 USD

19.72
376,763

+0.61 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $19.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?

Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Looks Good: Stock Adds 5.8% in Session

Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.

Retrophin (RTRX) Tops Q1 Earnings and Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?

Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

Kinjel Shah headshot

5 Beaten-Down Biotech Stocks Set to Rebound in 2020

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

Top Ranked Momentum Stocks to Buy for November 7th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 7th

Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to Decline

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

Retrophin Down on Neurological Disorder Drug Study Failure

Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

Implied Volatility Surging for Retrophin (RTRX) Stock Options

Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of -10.53% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View

Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

Retrophin (RTRX) Reports Q3 Loss, Lags Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of -750.00% and -8.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?